Recent developments include narrowing net losses for FY25, plans to submit an IDE for the CBGM in Q2 2026, successful repurchase of Series A warrants, clinical study progress, and presentations at scientific conferences.

• Glucotrack reported a narrowed net loss for FY25 and plans to submit an Investigational Device Exemption (IDE) for its continuous blood glucose monitor (CBGM) in Q2 2026 [N1].
• The company successfully repurchased over 90% of its Series A warrants as part of a capital formation strategy [N3].
• Investigational continuous glucose monitor showed accuracy in a first-in-human study [N4].
• Glucotrack appointed Dr. Victoria E. Carr-Brendel to its Board of Directors [N5].
• The company formed a patient advisory board to enhance development of the CBGM [N6].
• Clinical study initiation in Australia for continuous blood glucose monitoring technology was announced for Q3 2025 [N7].
• Glucotrack presented first-in-human results of the CBGM at the 2025 ATTD conference [N8].
• The company is scheduled to present at the TechBio Showcase 2025 [N2].

Glucotrack's implantable CBGM technology addresses key barriers to CGM adoption such as discomfort, inconvenience, and device visibility by offering a long-term implant with minimal calibration and no external wearable components. Positive preclinical and initial human study results demonstrate safety and promising sensor longevity, which could differentiate the product in the diabetes monitoring market. The company's ISO 13485 certification and partnerships with experienced contract manufacturers support quality production. The planned U.S. clinical trial program and ongoing FDA discussions represent important steps toward regulatory approval. The formation of a patient advisory board and presentation of clinical data at scientific conferences indicate active engagement with the diabetes community and stakeholders [N1][N4][N6][N8].

Glucotrack has a history of operating losses and limited revenue, with significant accumulated deficits and liquidity constraints as of Q1 2026. The company faces Nasdaq listing risks due to its stock price being below the minimum bid price requirement, which could lead to delisting and reduced investor confidence. The implantable CGM market is competitive, dominated by established players with greater financial and operational resources. Clinical development and regulatory approval processes are costly, lengthy, and uncertain, with prior clinical studies requiring protocol amendments and study closures. Manufacturing depends on third-party contract manufacturers, which may pose risks if supply or quality issues arise. The company also faces risks related to internal control weaknesses and reimbursement uncertainties [S1][S2][N3].

Glucotrack's potential competitive advantages include its implantable CBGM technology that measures glucose directly in the blood with minimal lag time, potentially offering greater accuracy and longer sensor longevity (up to three years) compared to existing CGMs that measure interstitial fluid and require frequent sensor replacement. The implant procedure leverages established cardiovascular device techniques and form factors, which may facilitate adoption. The company has developed proprietary sensor chemistry and has ISO 13485 certified manufacturing partnerships. However, the company faces significant competition from well-established CGM providers with greater resources, brand recognition, and market access. The implantable CGM market is highly regulated and requires extensive clinical validation and reimbursement approvals, which may pose barriers to entry for competitors but also risks for Glucotrack.

• Nasdaq Listing Risk: The company’s common stock has been below Nasdaq’s minimum bid price requirement, leading to a Staff Determination to delist unless an appeal or corrective action occurs, which could adversely affect liquidity, investor confidence, and capital raising ability [S2].
• Liquidity Constraints: As of March 31, 2026, Glucotrack had limited cash and current assets relative to current liabilities, with a current ratio below 1, indicating potential challenges in meeting short-term obligations [S2].
• Clinical and Regulatory Risk: The implantable CBGM requires extensive clinical trials and FDA approval. Prior clinical studies have been closed or amended, and the company’s IDE submission is pending. Failure to obtain regulatory approval would impede commercialization [S1].
• Competitive Risk: The CGM market is dominated by established companies with greater resources, brand recognition, and distribution networks, which may limit Glucotrack’s market penetration [S1].
• Manufacturing and Quality Risk: Dependence on third-party contract manufacturers for implantable device components introduces risks related to production capacity, quality control, and regulatory compliance [S1].
• Financial Reporting Risk: The company has identified material weaknesses in internal controls over financial reporting and is implementing remediation measures, but risks remain that could affect financial statement reliability [S1].
• Reimbursement Risk: Adequate reimbursement from Medicare and third-party payors is critical for commercial success. Coverage decisions are uncertain and may delay or limit market adoption [S1].

• Glucotrack, Inc. is a Delaware medical device company focused on developing an implantable continuous blood glucose monitor (CBGM) for Type 1 and insulin-using or hypoglycemia-risk Type 2 diabetes patients [S1].
• The company originally developed a non-invasive glucose monitor (Glucotrack) with CE Mark approval but ceased commercialization and withdrew the CE Mark in 2023 to focus on the implantable CBGM [S1].
• The Glucotrack CBGM uses an intravascular approach with a subcutaneous implant connected to a lead placed directly into a blood vessel, enabling continuous blood glucose measurement with effectively zero lag time, unlike current CGMs measuring interstitial fluid glucose [S1].
• Preclinical studies demonstrated sensor longevity of at least two years, with in vitro and in silico modeling supporting feasibility of three-year implant life [S1].
• Multiple animal studies showed good safety, functionality, and accuracy up to six months [S1].
• A first-in-human acute study in 2025 with 8 in-hospital patients demonstrated safety and device performance, meeting endpoints with no serious safety events [S1].
• A long-term multicenter feasibility study in Australia was initiated but later closed due to protocol and product update considerations; the company is refocusing on a U.S. clinical trial program pending FDA Investigational Device Exemption (IDE) submission planned for Q2 2026 [S1].
• The company has been in presubmission discussions with the FDA since Q2 2025 regarding clinical trial design and IDE approval [S1].
• Glucotrack holds ISO 13485:2016 certification for quality management systems relevant to medical device design and manufacturing, with successful annual audits and no major nonconformities [S1].
• The executive management team includes CEO Paul V. Goode, CFO Peter C. Wulff, and senior leaders with extensive experience in diabetes and medical device industries [S1].
• The Board of Directors includes members with backgrounds at major diabetes and medical device companies such as Dexcom, Medtronic, and Abbott [S1].
• The company has incurred net losses since inception, with a net loss of approximately $4.3 million for Q1 2026 and an accumulated deficit of about $151.8 million as of December 31, 2025 [S1, S2].
• As of March 31, 2026, Glucotrack had cash and cash equivalents of approximately $3.9 million, current assets of $4.2 million, current liabilities of $5.0 million, a current ratio of 0.85, and a cash ratio of 0.79, indicating liquidity constraints [S2].
• The company’s common stock has been below Nasdaq’s $1.00 minimum bid price listing requirement, leading to a Staff Determination to delist the stock unless an appeal or corrective action occurs [S2].
• Glucotrack has repurchased over 90% of its Series A warrants as part of a capital formation strategy [N3].
• The company has formed a patient advisory board and initiated clinical studies to enhance development of the CBGM [N6, N7].
• Glucotrack presented first-in-human results of the CBGM at the 2025 ATTD conference and other scientific meetings [N8].
• The company is collaborating with contract manufacturers certified under ISO 13485 for production of implantable system components [S1].
• Glucotrack’s CBGM technology aims to address barriers to CGM adoption such as discomfort, inconvenience, and device visibility, with potential advantages in accuracy, longevity, and usability [S1].
• The company faces competition from established CGM providers like Abbott, Dexcom, and Medtronic, which have greater resources and market presence [S1].
• Glucotrack is preparing reimbursement strategies for the CBGM product, including coverage for the device and implantation procedures, recognizing the importance of third-party payor reimbursement [S1].
• The company has identified material weaknesses in internal controls over financial reporting and is implementing remediation measures [S1].